Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 8
Submit an article Journal homepage
252
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

Ahmed SawasCenter for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2448-0144
ORCID Icon,
Helen MaCenter for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0002-0416-5115
ORCID Icon,
Andrei ShustovDivision of Hematology, University of Washington, Seattle, WA, USA;
,
Pamela HsuSpectrum Pharmaceuticals, Irvine, CA, USA;
,
Gajanan BhatSpectrum Pharmaceuticals, Irvine, CA, USA;
,
Mark AcostaAcrotech BioPharma, East Windsor, NJ, USA;
,
Steven HorwitzMemorial Sloan-Kettering Cancer Center, New York, NY, USA
&
Owen A. O’ConnorCenter for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA;
show all
Pages 2003-2007 | Received 09 Nov 2019, Accepted 29 Mar 2020, Published online: 26 Apr 2020

References

  • Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
  • Hamadani M, Abu Kar SM, Usmani SZ, et al. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014;51(1):73–86.
  • Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–1577.
  • O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499.
  • Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017;35(4):914–917.
  • Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6(4):202–208.
  • Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466–1469.
  • Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901–1903.
  • Cortes JR, Ambesi-Impiombato A, Couronné L, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259–273.e7.
  • Zhang YW, Wang Z, Xie W, et al. Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol Cell. 2017;65(2):323–335.
  • Delarue R, Dupuis J, Sujobert P, et al. Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas. Blood. 2016;128(22):4164–4164.
  • Lemonnier F, Dupuis J, Sujobert P, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305–2309.
  • Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015;171(2):215–226.
  • O’Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase I study. Blood. 2019;134(17):1395–1405.
  • Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.